BlueRock Therapeutics

BlueRock Therapeutics, **founded in 2016**, is a leading engineered cell therapy company in the **United States**. The company is **focused on developing regenerative medicines for intractable diseases** in the fields of **neurology, cardiology, and immunology**. BlueRock Therapeutics' **cell+gene platform** aims to harness the power of cells to create innovative medicines. Their **cell differentiation technology** is designed to produce authentic cell therapies, which can be engineered for additional function, offering the potential to replace damaged or degenerated tissue and **restore lost function**. Driven by scientific innovation and ethical standards, BlueRock Therapeutics aims to bring **transformative treatments** to those in need. The company prides itself on fostering a culture of **excellence and urgency** in the field of regenerative medicine. Notably, in December 2016, BlueRock Therapeutics secured a significant **$225.00M Series A investment**, with **Versant Ventures** and **Leaps by Bayer** participating as **investors**. Passionate about their mission, the company is actively **expanding their team** and invites individuals seeking rewarding career opportunities to **connect on LinkedIn or through their website**. With its strong vision and notable financial backing, BlueRock Therapeutics holds promise in driving **innovation** in the biopharma, biotechnology, and healthcare industries.